Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-controlled, Open-Label, Multicenter, Study of Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Subjects With Inhibitors Undergoing the First ITI Treatment

NCT03093480 is registered in ClinicalTrials.gov with Bioverativ, a Sanofi company as lead sponsor.

NCT NCT03093480
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03093480 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-controlled, Open-Label, Multicenter, Study of Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Subjects With Inhibitors Undergoing the First ITI Treatment
Lead sponsor
Bioverativ, a Sanofi company
Phase
Phase 4
Overall status
Completed
Start date
December 8, 2017
Completion date
February 16, 2021
Enrollment
16 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a with inhibitors